Nanotechnology: An Evolution in Tissue Preservation and Focal-Targeted Oncologic Therapy

Kara L. Watts, Joshua M. Stern

Research output: Chapter in Book/Report/Conference proceedingChapter


The treatment of urologic malignancies has evolved toward tissue-sparing and targeted therapies. Nanotechnology is at the forefront of these advances, particularly in the diagnosis and treatment of prostate and renal cancers. In diagnostics, computed tomography (CT) and magnetic resonance imaging (MRI) combined with lymphotropic nanoparticles significantly improve the detection of metastatic lymph nodes and cancer staging. In therapeutics, nanoparticles passively and actively target tumor cells to focally ablate using a variety of thermal ablative techniques. Targeted therapy using nanoparticles labeled with chemotherapeutic agents has also shown success. The field of nanotechnology holds considerable promise for the future of urologic cancer therapy in the era of tissue preservation. Future studies are needed to improve the development and use of these particles to further advance urologic cancer theranostics.

Original languageEnglish (US)
Title of host publicationManagement of Urologic Cancer
Subtitle of host publicationFocal Therapy and Tissue Preservation
Number of pages19
ISBN (Electronic)9781118868126
ISBN (Print)9781118868089
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Nanotechnology: An Evolution in Tissue Preservation and Focal-Targeted Oncologic Therapy'. Together they form a unique fingerprint.

Cite this